Funding a Start-up? Friends Lead the Way

University scientists seeking to commercialize their research results most often turn to friends and family for startup funding. Nearly 21% of companies started by professors in fiscal year 2004 received initial funding from friends and family, compared to 10.7% tapped from angels and 5.7% from angel networks, according to the latest survey from the Northbrook, Ill-based Association of University Technology Managers (AUTM).1 Forty-nine percent of funding came from individuals vs. a

Written byTed Agres
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

University scientists seeking to commercialize their research results most often turn to friends and family for startup funding. Nearly 21% of companies started by professors in fiscal year 2004 received initial funding from friends and family, compared to 10.7% tapped from angels and 5.7% from angel networks, according to the latest survey from the Northbrook, Ill-based Association of University Technology Managers (AUTM).1 Forty-nine percent of funding came from individuals vs. approximately 45% received from institutions. "Far from marauding bands of venture capitalists sweeping in and reaping profits from the back of federal research, these data show that most startup funding comes from friends, family, and other individual investors," says Ashley Stevens, AUTM survey editor and director of Boston University's Office of Technology Transfer.

Nearly 460 new companies were started from US university research in fiscal 2004, almost 25% more than in 2003. Friends and families typically invest $10,000 to $20,000 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies